Search Result

Results for "

ERBB inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Akt (12) Apoptosis (21) Autophagy (22) Bacterial (1) Btk (2) c-Met/HGFR (6) CD44 (1) CDK (2) CXCR (6) Drug Metabolite (1) EGFR (99) ERK (4) Ferroptosis (16) FGFR (1) Glutathione Peroxidase (2) Heme Oxygenase (HO) (2) Histamine Receptor (6) HSP (1) IKK (1) Indoleamine 2,3-Dioxygenase (IDO) (2) Isotope-Labeled Compounds (12) Itk (1) JAK (1) Keap1-Nrf2 (2) MAPKAPK2 (MK2) (1) Mitosis (1) Orthopoxvirus (4) p38 MAPK (7) Paraptosis (1) PARP (1) PDGFR (1) PI3K (1) PI4K (1) PROTACs (1) Raf (1) Ras (1) Reactive Oxygen Species (ROS) (2) Reference Standards (18) Src (4) Survivin (1) TGF-β Receptor (2) Trk Receptor (1) Tyrosine Hydroxylase (2)
By Research Areas:	Cancer (94) Cardiovascular Disease (3) Endocrinology (5) Infection (13) Inflammation/Immunology (10) Metabolic Disease (6) Neurological Disease (7)
Oligonucleotides:	Aptamers (1)

108

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10261

Afatinib Maximum Cited Publications 103 Publications Verification BIBW 2992	EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK	Cancer
Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of *ErbB* family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR ^wt, EGFR ^L858R, EGFR ^L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

HY-50898

Lapatinib 90+ Cited Publications GW572016; GW2016	EGFR Autophagy Ferroptosis	Infection Neurological Disease Metabolic Disease Cancer
Lapatinib (GW572016) is a potent, orally active inhibitor of the *ErbB-2* and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and *ErbB-2* of 10.2 and 9.8 nM, respectively .

HY-13272

Dacomitinib 25+ Cited Publications PF-00299804; PF-299804	EGFR Apoptosis	Cancer
Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the *ERBB* family of kinases with IC₅₀s of 6 nM, 45.7 nM and 73.7 nM for EGFR, *ERBB2, and ERBB4*, respectively .

HY-132842

Sunvozertinib 4 Publications Verification DZD9008	EGFR Btk	Cancer
Sunvozertinib (DZD9008) is a potent *ErbBs* (EGFR, Her2, especially mutant forms) and BTK inhibitor. Sunvozertinib shows IC₅₀s of 20.4, 20.4, 1.1, 7.5, and 80.4 nM for EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, and Her2 Exon20 YVMA, and EGFR WT A431, respectively (patent WO2019149164A1, example 52) .

HY-10261A

Afatinib dimaleate Maximum Cited Publications 103 Publications Verification BIBW 2992MA2	EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK	Cancer
Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of *ErbB* family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR ^wt, EGFR ^L858R, EGFR ^L858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

HY-P99275

Patritumab 1 Publications Verification AMG-888; U3-1287	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to *ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits* the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-10367

Canertinib 5+ Cited Publications CI-1033; PD-183805	EGFR Orthopoxvirus	Infection Cancer
Canertinib (CI-1033;PD-183805) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and *ErbB2* autophosphorylation with IC₅₀s of 7.4 and 9 nM. Canertinib is active against vaccinia virus respiratory infection in mice .

HY-B0793

AZ-5104 5+ Cited Publications	EGFR	Cancer
AZ-5104 is an active, demethylated metabolite of AZD 9291. AZ-5104 is an EGFR inhibitor with IC₅₀s of 1, 6, 1, 25 and 7 nM for EGFR ^L858R/T790M, EGFR ^L858R, EGFR ^L861Q, EGFR and ErbB4, respectively.

HY-50898A

Lapatinib ditosylate 90+ Cited Publications GW572016 ditosylate; GW2016 ditosylate	EGFR Autophagy Ferroptosis	Infection Neurological Disease Metabolic Disease Cancer
Lapatinib ditosylate (GW572016 ditosylate) is a potent, orally active inhibitor of the *ErbB-2* and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and *ErbB-2* of 10.2 and 9.8 nM, respectively .

HY-13050

Sapitinib 15+ Cited Publications AZD-8931	EGFR	Cancer
Sapitinib (AZD-8931) is a reversible, ATP competitive EGFR inhibitor of with IC₅₀s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively.

HY-100848

TX1-85-1 2 Publications Verification	EGFR	Cancer
TX1-85-1 is an irreversible Her3 (ErbB3) inhibitor with an IC₅₀ of 23 nM. TX1-85-1 is also the first selective Her3 ligand, which forms a covalent bond with Cys721 located in the ATP-binding site of Her3. TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling .

HY-50898B

Lapatinib ditosylate monohydrate 90+ Cited Publications GW572016 ditosylate monohydrate; GW2016 ditosylate monohydrate	EGFR Autophagy Ferroptosis	Infection Metabolic Disease Cancer
Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent, orally active inhibitor of the *ErbB-2* and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and *ErbB-2* of 10.2 and 9.8 nM, respectively .

HY-32718

Pelitinib 5+ Cited Publications EKB-569; WAY-EKB 569	EGFR Src	Cancer
Pelitinib (EKB-569;WAY-EKB 569) is an irreversible inhibitor of EGFR with an IC₅₀ of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC₅₀s of 282, 800, and 1255 nM, respectively.

HY-P99268

Seribantumab SAR 256212; MM 121	EGFR Apoptosis	Cancer
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

HY-10322

Falnidamol 4 Publications Verification BIBX 1382	EGFR	Cancer
Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC₅₀ of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC₅₀=3.4 μM) and a range of other related tyrosine kinases (IC₅₀>10 μM). Falnidamol is a pyrimido-pyrimidine compound and has anti-cancer activity .

HY-10045

AEE788 3 Publications Verification NVP-AEE 788	EGFR Apoptosis	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
AEE788 is an orally active inhibitor targeting EGFR and *ErbB2* with IC₅₀ values of 2 and 6 nM, respectively ^[1][2][3].

HY-10367A

Canertinib dihydrochloride 5+ Cited Publications CI-1033 dihydrochloride; PD-183805 dihydrochloride	EGFR Orthopoxvirus	Infection Cancer
Canertinib dihydrochloride (CI-1033 dihydrochloride) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and *ErbB2* autophosphorylation with IC₅₀s of 7.4 and 9 nM. Canertinib dihydrochloride is active against vaccinia virus respiratory infection in mice .

HY-P99866

Duligotuzumab MEHD-7945A; RG 7597	EGFR Akt p38 MAPK Apoptosis	Cancer
Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody targeting EGFR. Duligotuzumab blocks the binding of ligands to these two receptors, inhibits downstream *HER/ErbB, AKT* and MAPK signaling pathways, induces antibody-dependent cellular cytotoxicity, reduces the proliferation and migration abilities of cancer cells, promotes apoptosis, exerts radiosensitizing effects, and reverses EGFR resistance in cancer cells. Duligotuzumab can be used in tumor-related research .

HY-18609

PD158780 4 Publications Verification	EGFR	Cancer
PD158780 is a potent EGFR family inhibitor with IC₅₀s of 8 pM, 49, 52, 52 nM for EGFR, ErbB2, ErbB3, and ErbB4, respectively.

HY-168438

ERBB agonist-1 1 Publications Verification	EGFR Akt ERK	Cardiovascular Disease
ERBB agonist-1 (Compound EF-1) is an agonist for *ERBB4, that activates the ERBB4 signaling pathway by inducing dimerization of the ERBB4 receptor with an EC₅₀* of 10.5 μM. ERBB agonist-1 induces phosphorylation of Akt and ERK1/2, reduces the collagen expression in cardiac fibroblasts, inhibits H₂O₂-induced cardiomyocyte death and Ang II (HY-13948)-induced cardiomyocyte hypertrophy. ERBB agonist-1 prevents fibrosis and exhibits cardioprotective efficacy in mouse models .

HY-13427

Allitinib tosylate 2 Publications Verification AST-1306 (TsOH)	EGFR	Cancer
Allitinib tosylate (AST-1306 (TsOH)) is an orally active and irreversible EGFR and *ErbB2* inhibitor with IC₅₀s of 0.5 and 3 nM, respectively. Allitinib tosylate also inhibits *ErbB4* with an IC₅₀ of 0.8 nM. Allitinib tosylate is an anilino-quinazoline compound and has anti-cancer activity

HY-13896

PD168393 3 Publications Verification	EGFR Autophagy Apoptosis	Cancer
PD168393 is a potent, selective and cell-permeable inhibitor of EGFR tyrosine kinase and *ErbB2. PD168393 irreversiblely inactivates EGF receptor ( IC₅₀*=0.7 nM) and is inactive against insulin receptor, PDGFR, FGFR and PKC .

HY-P99304

Lumretuzumab Anti-Human ERBB3 Recombinant Antibody	EGFR PI3K Akt p38 MAPK	Cancer
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody. Lumretuzumab effectively inhibits the activity of key oncogenic signaling pathways such as PI3K/AKT and MAPK. Lumretuzumab has been optimized through glycosyl engineering to enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Lumretuzumab can be used to study HER3-positive, HER2-low-expressing solid tumors, especially breast cancer .

HY-B0426A

Olopatadine hydrochloride ALO4943A; KW4679	Histamine Receptor CXCR	Infection Neurological Disease Metabolic Disease Inflammation/Immunology
Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of *ErbB3A/HER3A*. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-15375

Allitinib 2 Publications Verification AST-1306; ALS 1306	EGFR	Cancer
Allitinib (AST-1306) is an orally active and irreversible EGFR and *ErbB2* inhibitor with IC₅₀s of 0.5 and 3 nM, respectively. Allitinib also inhibits *ErbB4* with an IC₅₀ of 0.8 nM. Allitinib is an anilino-quinazoline compound and has anti-cancer activity .

HY-14674

CP-724714 4 Publications Verification	EGFR Apoptosis	Cancer
CP-724714 is a potent, selective and orally active ErbB2 (HER2) tyrosine kinase inhibitor, with an IC₅₀ of 10 nM. CP-724714 displays a marked selectivity against EGFR kinase (IC₅₀=6400 nM). CP-724714 potently inhibits ErbB2 receptor autophosphorylation in intact cells. Antitumor activities .

HY-20878

Tyrphostin AG 879 3 Publications Verification AG 879	Trk Receptor EGFR Apoptosis	Cancer
Tyrphostin AG 879 (AG 879) is a tyrosine kinase inhibitor that inhibits TrKA phosphorylation (IC₅₀ of 10 μM), but not TrKB and TrKC. Tyrphostin AG 879 is also a selective *ErbB2* tyrosine kinase inhibitor with an IC₅₀ of 1 μM, and has at least 500-fold higher selectivity to *ErbB2* than EGFR. Tyrphostin AG 879 has anticancer activity .

HY-118263

Dacomitinib hydrate 25+ Cited Publications PF-00299804 hydrate; PF-299804 hydrate	EGFR	Cancer
Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC) .

HY-103443

HKI-357	EGFR	Cancer
HKI-357 is an irreversible dual inhibitor of EGFR and *ERBB2* with IC₅₀s of 34 nM and 33 nM, respectively. HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation .

HY-103440

*EGFR/ErbB-2/ErbB-4 inhibitor-3*	EGFR	Cancer
EGFR/ErbB-2/ErbB-4 inhibitor-3 (compound 29) is a potent tyrosine kinase inhibitor with IC₅₀s of 0.3, 1.1, 0.5, 2.5, 24 nM for erbB1, erbB2, erbB4, EGF, HER, respectively . EGFR/ErbB-2/ErbB-4 inhibitor-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10346

AV-412 5 Publications Verification MP412	EGFR	Cancer
AV-412 (MP412) is an EGFR inhibitor with IC₅₀s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFR ^L858R, EGFR ^T790M, EGFR ^L858R/T790M and ErbB2, respectively.

HY-101042

AG-494 Tyrphostin AG 494	EGFR CDK	Cancer
AG-494 (Tyrphostin AG 494) is a potent and selective EGFR tyrosine kinase inhibitor (IC₅₀=0.7 μM). AG-494 inhibits the autophosphorylation of EGFR, ErbB2, HER1-2 and PDGF-R with IC₅₀s 1.1, 39, 45 and 6 μM, respectively. AG-494 blocks Cdk2 activation and inhibits EGF-dependent DNA synthesis .

HY-123035

Gamendazole	HSP Akt EGFR	Endocrinology
Gamendazole, an indazole carboxylic acid (ICA), is an orally active, selective HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A) inhibitor. Gamendazole binds to the C-terminal nucleotide binding pocket of HSP90 and cause downregulation of clients AKT1 and ERBB2, but stabilizes the HSP90 heterocomplex. Gamendazole specifically inhibits the actin bundling function of EEF1A1, but does not bind to the nucleotide docking pocket nor inhibits the ribosome charging or protein translation functions of EEF1A1. Gamendazole, an antispermatogenic compound with antifertility effects, has the potential for reversible non-hormonal male contraceptive agent research .

HY-116437

Selatinib 1 Publications Verification	EGFR	Cancer
Selatinib is a reversible and orally active dual EGFR and *ErbB2* inhibitor with IC₅₀s of 13 nM and 22.5 nM, respectively. Selatinib has anticancer effects .

HY-W062109

Olopatadine	Histamine Receptor CXCR	Inflammation/Immunology
Olopatadine (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of *ErbB3A/HER3A*. Olopatadine can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-135366

HPN-01	IKK	Inflammation/Immunology
HPN-01 is a potent and selective IKK inhibitor, with pIC₅₀ values of 6.4, 7.0 and <4.8 for IKK-α, IKK-β and IKK-ε, respectively. HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2 .

HY-50898S4

Lapatinib-d7 GW572016-d₇; GW2016-d₇	Isotope-Labeled Compounds Autophagy EGFR Ferroptosis	Cancer
Lapatinib-d₇ (GW572016-d₇) is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent, orally active inhibitor of the *ErbB-2* and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and *ErbB-2* of 10.2 and 9.8 nM, respectively .

HY-118532

Tyrphostin AG30 1 Publications Verification AG30	EGFR	Cancer
Tyrphostin AG30 (AG30) is a potent and selective EGFR tyrosine kinase inhibitor. Tyrphostin AG30 (AG30) selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts .

HY-100499

Tyrphostin AG 528 1 Publications Verification Tyrphostin B66; AG 528	EGFR	Cancer
Tyrphostin AG 528 is an inhibitor of EGFR and *ErbB2* with IC₅₀s of 4.9 and 2.1 μM, respectively. Tyrphostin AG 528 (Tyrphostin B66) is a protein tyrosine kinase inhibitor, with IC₅₀s of 4.9 μM for epidermal growth factor receptors (EGFR) and 2.1 μM for *ErbB2* . Tyrphostin AG 528 is also an anticancer agent .

HY-P991240

CDX-3379 KTN-3379	EGFR	Cancer
CDX-3379 is a humanized monoclonal antibody inhibitor targeting *ErbB3. CDX-3379 binds to ErbB3, blocking the dimerization of ErbB3 with other receptors, thereby inhibiting* the phosphorylation of ErbB3. CDX-3379 can inhibit the growth and proliferation of tumor cells. CDX-3379 is promising for research of tumors expressing ErbB3 and NRG1, such as HNSCC .

HY-103441

JNJ28871063 hydrochloride	EGFR	Cancer
JNJ28871063 hydrochloride is an orally active, highly selective and ATP competitive *pan-ErbB* kinase** inhibitor with IC₅₀ values of 22 nM, 38 nM, and 21 nM for ErbB1, ErbB2, and ErbB4, respectively. JNJ28871063 hydrochloride inhibits phosphorylation of functionally important tyrosine residues in both EGFR and ErbB2. JNJ28871063 hydrochloride crosses the blood-brain barrier and has antitumor activity in human tumor xenograft models that overexpress EGFR and ErbB2 .

HY-175809

SRT6	CD44 Src EGFR MAPKAPK2 (MK2)	Cancer
SRT6 is a CD44 inhibitor. SRT6 exerts antiproliferative activity in CD44 ⁺ breast cancer and lung cancer cells. SRT6 inhibits CD44-associated SRC kinase, as well as EGFR, *ERBB2, ERBB4, MAP3K10* and MAPKAPK2. SRT6 can be used for the research of breast cancer and lung cancer .

HY-150023

BI-1622	EGFR Itk PI4K Btk CDK Raf JAK	Cancer
BI-1622 is an orally active, potent and highly selective HER2 (ERBB2) inhibitor, with an IC₅₀ of 7 nM. BI-1622 shows greater than 25-fold selectivity over EGFR. BI-1622 shows high antitumor efficacy in vivo in xenograft mouse tumor models with engineered H2170 and PC9 cells and had a favorable agent metabolism and pharmacokinetics profile .

HY-15844

AG-825 1 Publications Verification Tyrphostin AG-825	EGFR Apoptosis Adrenergic Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
AG-825 is a selective, ATP-competitive, tyrosine phosphorylation *ErbB2* inhibitor with an IC₅₀ of 0.35 μM. AG825 significantly accelerates Apoptosis of human neutrophils. AG-825 increases β1AR density. AAG-825 has anticancer and anti-inflammatory activities. AAG-825 can be used in cardiovascular disease research .

HY-118998

TX2-121-1	PROTACs EGFR ERK Akt	Cancer
TX2-121-1 is a potent and selective Her3 (ErbB3) degrader that contains a hydrophobic adamantane moiety. TX2-121-1 has an IC₅₀ of 49 nM for Her3. TX2-121-1 inhibits Her3-dependent signaling and heterodimerization of Her3. TX2-121-1 has the ability to inhibit cell proliferation. TX2-121-1 can be used in the study of tumors. (Pink: Her3 inhibitor (HY-164988); Black: Linker; Blue: Adamantane (HY-N2427)) .

HY-10261R

Afatinib (Standard) BIBW 2992 (Standard)	Reference Standards EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK	Cancer
Afatinib (Standard) is the analytical standard of Afatinib. This product is intended for research and analytical applications. Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

HY-50898S1

Lapatinib-d7 dihydrochloride GW572016-d7 dihydrochloride; GW2016-d7 dihydrochloride	Isotope-Labeled Compounds EGFR Autophagy Ferroptosis	Cancer
Lapatinib-d₇ dihydrochloride is the deuterium labeled Lapatinib dihydrochloride. Lapatinib (GW572016) dihydrochloride is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898S

Lapatinib-d4 GW572016-d₄; GW2016-d₄	EGFR Autophagy Ferroptosis	Cancer
Lapatinib-d₄ is the deuterium labeled Lapatinib (HY-50898). Lapatinib is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-14347

EBE-A22 1 Publications Verification	EGFR	Cancer
EBE-A22 is a derivative of PD153035, which can inhibit the phosphorylation of ErbB-1, but EBE-A22 does not have this activity.

HY-10346A

AV-412 free base 5 Publications Verification MP-412 free base	EGFR	Cancer
AV-412 free base (MP-412 free base) is an EGFR inhibitor with IC₅₀s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFR ^L858R, EGFR ^T790M, EGFR ^L858R/T790M and ErbB2, respectively.

Cat. No.	Product Name	Target	Research Area	Image

HY-P99275

Patritumab 1 Publications Verification AMG-888; U3-1287	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to *ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits* the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-P99268

Seribantumab SAR 256212; MM 121	EGFR Apoptosis	Cancer
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

HY-P99866

Duligotuzumab MEHD-7945A; RG 7597	EGFR Akt p38 MAPK Apoptosis	Cancer
Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody targeting EGFR. Duligotuzumab blocks the binding of ligands to these two receptors, inhibits downstream *HER/ErbB, AKT* and MAPK signaling pathways, induces antibody-dependent cellular cytotoxicity, reduces the proliferation and migration abilities of cancer cells, promotes apoptosis, exerts radiosensitizing effects, and reverses EGFR resistance in cancer cells. Duligotuzumab can be used in tumor-related research .

HY-P99304

Lumretuzumab Anti-Human ERBB3 Recombinant Antibody	EGFR PI3K Akt p38 MAPK	Cancer
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody. Lumretuzumab effectively inhibits the activity of key oncogenic signaling pathways such as PI3K/AKT and MAPK. Lumretuzumab has been optimized through glycosyl engineering to enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Lumretuzumab can be used to study HER3-positive, HER2-low-expressing solid tumors, especially breast cancer .

HY-P991240

CDX-3379 KTN-3379	EGFR	Cancer
CDX-3379 is a humanized monoclonal antibody inhibitor targeting *ErbB3. CDX-3379 binds to ErbB3, blocking the dimerization of ErbB3 with other receptors, thereby inhibiting* the phosphorylation of ErbB3. CDX-3379 can inhibit the growth and proliferation of tumor cells. CDX-3379 is promising for research of tumors expressing ErbB3 and NRG1, such as HNSCC .

HY-P991243

MP-RM-1	EGFR Akt	Cancer
MP-RM-1 is an antibody-based, non-competitive *ErbB-3* inhibitor with a K_d value of 32.7 nM. MP-RM-1 inhibits both ligand-dependent and ligand-independent ErbB-3 activation, blocks ErbB-2/ErbB-3 heterodimerization, induces ErbB-3 internalization and degradation, and suppresses the phosphorylation of downstream Akt. MP-RM-1 exerts its antagonistic effect through a non-competitive mechanism. MP-RM-1 inhibits tumor growth in melanoma and prostate cancer xenograft models in nude mice and reduces the proliferative activity of tumor cells .

HY-P991244

REGN-1400	EGFR	Cancer
REGN-1400 is a humanized monoclonal antibody inhibitor targeting *ErbB3. REGN-1400 reduces tumor cell proliferation by inhibiting* ErbB3 and blocking related signaling pathways. REGN-1400 is promising for research of solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and squamous cell carcinoma of the head and neck (SCCHN) .

HY-P991241

Anti-ERBB3/HER3 (29Z6)	EGFR	Cancer
Anti-ERBB3/HER3 (29Z6) is an antibody inhibitor, targeting to human ERBB3/HER3.

HY-P991245

Anti-ERBB3/HER3 (SGP1)	EGFR	Cancer
Anti-ERBB3/HER3 (SGP1) is a human monoclonal antibody (mAb) targeting *ERBB3/HER3. Anti-ERBB3/HER3 (SGP1) inhibits* Neuregulin stimulated growth of cultured breast cancer cells. Anti-ERBB3/HER3 (SGP1) can be used in breast cancer research .

HY-P991979

Erbicin	EGFR	Cancer
Erbicin is a single-chain antibody against the human *ErbB2* receptor . Erbicin specifically binds to ErbB2-positive cells, inhibits receptor autophosphorylation, and is internalized by target cells. Erbicin can be used in breast cancer-related research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0353

Curdione 2 Publications Verification (+)-Curdione	Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Other Diseases Curcuma phaeocaulis Valeton Plants Disease Research Fields Source Classification Zingiberaceae	Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Autophagy Glutathione Peroxidase Keap1-Nrf2 Heme Oxygenase (HO) TGF-β Receptor Indoleamine 2,3-Dioxygenase (IDO)
Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC₅₀ = 1.1 μM) and cyclooxygenase 2 expression .

HY-B0426A

Olopatadine hydrochloride ALO4943A; KW4679	Structural Classification Alkaloids Classification of Application Fields Ketones, Aldehydes, Acids Other Alkaloids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Histamine Receptor CXCR
Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of *ErbB3A/HER3A*. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-W062109

Olopatadine	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Histamine Receptor CXCR
Olopatadine (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of *ErbB3A/HER3A*. Olopatadine can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-B0426AR

Olopatadine hydrochloride (Standard) ALO4943A (Standard); KW4679 (Standard)	Structural Classification Alkaloids Ketones, Aldehydes, Acids Other Alkaloids Endogenous metabolite Source Classification	Reference Standards Histamine Receptor CXCR
Olopatadine (hydrochloride) (Standard) is the analytical standard of Olopatadine (hydrochloride). This product is intended for research and analytical applications. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of *ErbB3A/HER3A*. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-N0353R

Curdione (Standard) (+)-Curdione (Standard)	Structural Classification Terpenoids Sesquiterpenes Curcuma phaeocaulis Valeton Plants Source Classification Zingiberaceae	Reference Standards Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Autophagy Glutathione Peroxidase Keap1-Nrf2 Heme Oxygenase (HO) TGF-β Receptor Indoleamine 2,3-Dioxygenase (IDO)
Curdione (Standard) is the analytical standard of Curdione. This product is intended for research and analytical applications. Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC₅₀ = 1.1 μM) and cyclooxygenase 2 expression .

Cat. No.	Product Name	Chemical Structure

HY-50898S4

Lapatinib-d7
Lapatinib-d₇ (GW572016-d₇) is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent, orally active inhibitor of the *ErbB-2* and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and *ErbB-2* of 10.2 and 9.8 nM, respectively .

HY-50898S1

Lapatinib-d7 dihydrochloride
Lapatinib-d₇ dihydrochloride is the deuterium labeled Lapatinib dihydrochloride. Lapatinib (GW572016) dihydrochloride is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898S

Lapatinib-d4
Lapatinib-d₄ is the deuterium labeled Lapatinib (HY-50898). Lapatinib is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-W062109S

Olopatadine-d6

Olopatadine-d₆ is the deuterium labeled Olopatadine. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-B0426AS

Olopatadine-d3 hydrochloride

Olopatadine-d₃ hydrochloride (ALO4943A-d₃) is the deuterium labeled Olopatadine hydrochloride. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-50898S2

Lapatinib-d5
Lapatinib-d₅ is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898S3

Lapatinib-d4-1
Lapatinib-d₄-1 is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898CS

Lapatinib-d4 tosylate
Lapatinib-d₄ (GW572016-d₄) tosylate is deuterium labeled Lapatinib (tosylate). Lapatinib (GW572016) tosylate is a potent, orally active inhibitor of the *ErbB-2* and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and *ErbB-2* of 10.2 and 9.8 nM, respectively .

HY-13272S3

Dacomitinib-d10
Dacomitinib-d₁₀ is deuterium labeled Dacomitinib. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC₅₀s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively .

HY-13272S2

Dacomitinib-d10 dihydrochloride
Dacomitinib-d₁₀ dihydrochloride is the deuterium labeled Dacomitinib dihydrochloride. Dacomitinib (PF-00299804) dihydrochloride is a specific and irreversible inhibitor of the ERBB family of kinases with IC₅₀s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively .

HY-W777297

Lapatinib-13C2,15N Ditosylate
Lapatinib- ¹³C₂, ¹⁵N Ditosylate is the ¹³C- and ¹⁵N-labeled Lapatinib ditosylate (HY-50898A). Lapatinib ditosylate (GW572016 ditosylate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-32718S

Pelitinib-d6
Pelitinib-d₆ (EKB-569-d₆) is the deuterium labeled Pelitinib. Pelitinib (EKB-569) is an irreversible inhibitor of EGFR with an IC₅₀ of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC₅₀s of 282, 800, and 1255 nM, respectively .

HY-B0793S1

AZ-5104-d2
AZ-5104-d₂ is the deuterium labeled AZ-5104. AZ-5104 is an EGFR inhibitor with IC₅₀s of 1 nM, 6 nM, 1 nM, 25 nM and 7 nM for EGFRL858R/T790M, EGFRL858R, EGFRL861Q, EGFR and ErbB4, respectively .

HY-B0426AS2

Olopatadine-d6 hydrochloride

Olopatadine-d₆ (ALO4943A-d₆; KW4679-d₆) hydrochloride is deuterium-labeled Olopatadine (hydrochloride) (HY-B0426A). Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

Cat. No.	Product Name		Classification

HY-160068

2-2(t) aptamer sodium		Aptamers
2-2(t) aptamer sodium is a 42-nucleotide trimeric complex of aptamer (2-2) targeting *ErbB-2. 2-2(t) aptamer sodium inhibits* the growth of gastric cancer cells in vitro and in vivo .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks